H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics (RLAY) to $16 from $20 and keeps a Buy rating on the shares. The firm says the Lirafugratinib out-licensing agreement “appears heavily back end-loaded.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics, Elevar Therapeutics enter licensing agreement
- Relay Therapeutics price target raised to $20 from $19 at H.C. Wainwright
- Relay Therapeutics Reports Q3 2024 Results and Advances
- Relay Therapeutics reports Q3 EPS (63c), consensus (77c)
- Relay Therapeutics participates in a conference call with JPMorgan